Novartis India Board of Directors

Get the latest insights into the leadership at Novartis India. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Christopher Snook Chairperson
Mrs. Shilpa Joshi WholeTime Director & CFO
Mr. Falin Majmudar Whole Time Director
Mr. Sandra Martyres Independent Director
Mr. Sanker Parameswaran Independent Director
Mr. Gira Sardesai Independent Director

Novartis India Share price

NOVARTIND

931.9

1.15 (-0.12%)
Last updated on 4 Sep, 2025 | 15:54 IST
BUYSELL
Today's High

942.50

Today's Low

930.10

52 Week Low

744.95

52 Week High

1248.00

The current prices are delayed, login to your account for live prices

Novartis India FAQs

The board at Novartis India consists of experienced professionals, including Mr. Christopher Snook , Mrs. Shilpa Joshi , and others, overseeing the company’s strategic and corporate governance.

Directors at Novartis India are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Christopher Snook is the current chairman at Novartis India.

Executive directors at Novartis India are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Novartis India adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Novartis India, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.